Statins and cognitive function in the elderly: The Cardiovascular Health Study

Neurology

Volumn 65, Issue 9, 2005, Pages 1388-1394

  Bernick, C ^a   Katz, R ^b   Smith, N L ^b   Rapp, S ^c   Bhadelia, R ^d   Carlson, M ^e   Kuller, L ^f  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CHOLESTEROL; ESTROGEN; STATINE DERIVATIVE;

AGED; ARTICLE; BRAIN ATROPHY; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; DATA ANALYSIS; DRUG EFFECT; DRUG USE; EDUCATION PROGRAM; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATIENT CODING; PATIENT EDUCATION; PRIORITY JOURNAL; SCORING SYSTEM; WHITE MATTER;

EID: 27644511663     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000182897.18229.ec     Document Type: Article

References (38)

1. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population based study. Neurology 2001;56:1683-1689.
2. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Br Med J 2001;322:1447-1451.
3. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
4. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg G, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case control study. Neurology 1995;45:1092-1096.
5. Evans R, Emsley C, Gao S, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population based study of African Americans. Neurology 2000;54:240-242.
6. Jick H, Zornberg GL, Jick S, Seshardri S, Drachman D. Statins and the risk of dementia. Lancet 2000;356:1627-1631.
7. Wolozin B, Kellman W, Ruosseau P, Celesia G, Siegal G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443.
8. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, et al. Statin therapy and risk of dementia in the elderly. Neurology 2004;63:1624-1628.
9. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. Pravastatin in elderly individuals at risk of vascular disease: a randomized controlled trial. Lancet 2002;360:1623-1630.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvistatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
11. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263-276.
12. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993;3:358-366.
13. Longstreth WT, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. Stroke 1996;27:1274-1282.
14. Teng EL, Shui HC. The Modified Mini Mental State (3MS) Examination. J Clin Psychiatry 1987;48:314-318.
15. Ives D, Fitzpatrick A, Bild D, et al. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol 1995;5:278-285.
16. Price T, Psaty B, O'Leary D, Burke G, Gardin J. Assessment of cerebrovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1993;3:504-507.
17. Bryan RN, Manolio TA, Schertz LD, et al. A method for using MR to evaluate the effects of cardiovascular disease on the brain. AJNR Am J Neuroradiol 1994;15:1625-1633.
18. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. Stroke 1994;25:318-327.
19. Bryan RN, Wells SW, Miller TJ, et al. Infarct like lesions in the brain. Radiology 1997;202:17-19.
20. Refolo LM, Pappolla Ma, Malester B, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000;7:321-331.
21. Haley R. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plague formation in Alzheimer's disease? Arch Neurol 2000;57:1410-1412.
22. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces Alzheimer's disease AB 42 and A B 40 levels in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-5861.
23. Simmons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of B amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-6464.
24. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidgenic pathway by its effects on the alpha secretase ADAM 10. Proc Natl Acad Sci USA 2001;98:5815-5820.
25. Simmons M, Keller P, Dichgans J, Schulz J. Cholesterol and Alzheimer's disease: is there a link? Neurology 2001;57:1089-1093.
26. Games D, Adams D, Alessandrini R, et al. Development of neuropathology similar to Alzheimer's disease in transgenic mice overexpressing the 717 B amyloid precursor protein. Nature 1995;373:523-528.
27. Buxbaum J, Cullen E, Friedhoff L. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front Biosci 2002;7:50-59.
28. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002;59:378-384.
29. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvistatin in normocholesterolemic patients with Alzheimer's disease: a 26 week randomized, placebo-controlled, double blind trial. Ann Neurol 2002;52:346-350.
30. Golde TE, Eckman CB. Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. DDT 2001;6:1049-1055.
31. Simons M, Keller P, Dichgans J, Schulz J. Cholesterol and Alzheimer's disease. Is there a link? Neurology 2001;57:1089-1093.
32. Fassbender K, Stroick M, Bertsch T, et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer's amyloid peptide. Neurology 2002;59:1257-1258.
33. Koudinov AR, Koudinova NV. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 2001;15:1858-1860.
34. Scanlon SM, Williams DC, Schloss P. Membrane cholesterol modulates serotonin transporter activity. Biochemistry 2001;40:10507-10513.
35. Kaesemeyer W, Caldwell R, Huang J, Caldwell R. Fravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol lowering actions. J Am Coll Cardiol 1999;33:234-241.
36. Davignon J, Laaksonen R. Low density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999;10:543-559.
37. Rosenson R, Tangney C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
38. Longstreth WT, Bernick C, Manolio TA, Bryan N, Jungreis C, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people. Arch Neurol 1998;55:1217-1225.